lixte biotechnology holdings (LIXT) Key Developments
Daniel Von Hoff Joins Lixte Biotechnology's Scientific Advisory Board
Jan 7 14
Lixte Biotechnology Holdings, Inc. announced the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board. Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen.
Lixte Biotechnology Holdings, Inc. Announces Initiation of a Materials Cooperative Research and Development Agreement With National Institute of Neurological Disorders and Stroke, National Institutes of Health
Dec 10 13
Lixte Biotechnology Holdings, Inc. has signed a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS, NIH). Under this agreement, the Surgical Neurology Branch of NINDS, NIH, will conduct research characterizing a variety of compounds proprietary to Lixte. This research will examine the compounds' potential for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases. Under an M-CRADA, a party provides research material, in this case proprietary compounds from Lixte's pipeline, for study by scientists at NIH. The exchange of materials is for research only and implies no endorsement of the materials on the part of either party.
Lixte Biotechnology Holdings, Inc. Announces Initiation of Phase I Trial of Lead Anti-Cancer Compound, Lb-100
Apr 25 13
Lixte Biotechnology Holdings, Inc. reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere(R)).
Lixte Biotechnology Holdings, Inc. Auditor Raises 'Going Concern' Doubt
Mar 15 13
Lixte Biotechnology Holdings, Inc. filed its 10-K on Mar 15, 2013 for the period ending Dec 31, 2012. In this report its auditor, Weinberg & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Lixte Biotechnology Holdings, Inc. Appoints Kathleen Mullinix to its Board of Directors
Nov 27 12
Lixte Biotechnology Holdings, Inc. announces the appointment of Kathleen Mullinix, PhD to the company's Board of Directors. From 2003 to 2006 Dr. Mullinix was an independent consultant on health sciences and biotechnology and in 2008 joined WellGen, Inc. as CEO, President and Director. Subsequently she continued her consulting, and joined the Office of Technology and Business Development, Mount Sinai School of Medicine, New York, in 2009 and became director of the office in 2010 serving to 2012.